"This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public."

Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

Holmium-166 Scout (QuiremScout®) has shown superior predictive value

29/10/2019 - LEUVEN, BELGIUM

​when compared to technetium-99m-macroaggregated albumin during SIRT work-up

Terumo Europe N.V. is proud to share our latest key publication regarding holmium-166 (QuiremSpheres®) Selective Internal Radiation Therapy (SIRT). On 9th August 2019, UMC Utrecht published its results from a recent study on the comparison of QuiremScout® to technetium-99m-macroaggregated albumin (99mTc-MAA) as a SIRT work-up which is used to select patients with liver cancer who will benefit from SIRT treatment.

The aim of this study was to analyze whether the intrahepatic distribution of QuiremScout® has a better agreement with the QuiremSpheres® distribution when compared with 99mTc-MAA. It has been indicated in several scientific papers, the widely used Tech-99m-MAA has limited predictive value.
This study included 53 patients which had been included in either phase 1 and phase 2 Holmium Embolization Particles for Arterial Radiotherapy (HEPAR) studies and showed QuiremScout® to have a superior predictive value for intrahepatic distribution in comparison to 99mTc-MAA.
 
“Previous studies already demonstrated that QuiremScout® is safe1 in this population and moreover a better predictor for lung shunting than to 99mTc-MAA. As a result, QuiremScout® allows for more accurate SIRT patient selection. Now, our study shows the potential of QuiremScout® to also improve the efficacy of SIRT, by allowing a more accurate and truly personalized pre-treatment activity planning.” says Maarten Smits MD PhD, first author of the article2.
 
“This is an important next step towards unlocking the full potential of QuiremScout®.” said Rijk de Jong, Medical Director of Quirem Medical. “Smits et al. publication further strengthens the evidence base of QuiremScout®, demonstrating superiority over 99mTc-MAA in the evaluation of the subsequent treatment. We believe this will translate into enhanced efficacy and safety for the benefit of patients undergoing SIRT procedures”
 
“This is a very exciting milestone for QuiremScout® and the next step in building the future for SIRT.” added Peter Coenen, President of Interventional systems Terumo EMEA. “This publication further validates the advantages of QuiremScout® over 99mTc-MAA during the SIRT work up, which we at Terumo believe is a vital step in advancing patient selection and optimizing dosimetry for better patient outcomes”.
 
Results from this trial are published in the European Journal of Nuclear Medicine Molecular Imaging 2019.
QuiremScout® is the first SIRT work-up product that utilizes the same technology as the therapeutic microspheres, which aims to optimize patient selection and advance treatment planning when compared to using 99mTc-MAA.
 
 

About Terumo

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with approximately US$6 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.
 

About Quirem Medical

At Quirem Medical, we develop and commercialize the next-generation Selective Internal Radiation Therapy (SIRT) microspheres based on the radioisotope Holmium-166. We believe the treatment outcome of unresectable liver cancer with SIRT can be optimized with Holmium-166 microspheres, which can be visualized and quantified to improve SIRT patient selection, treatment planning and treatment verification. Our innovative Holmium-166 platform technology provides physicians a complete CE-marked SIRT solution including QuiremScout®, QuiremSpheres® and the supporting dosimetry software 
Q-SuiteTM.


1 Braat AJAT et al. Eur Radiol 2017
2 Smits, et al. Eur. J. Nucl. Med. Mol. Imaging 2019